際際滷

際際滷Share a Scribd company logo

CAF+CTG+iPRF.pptx

Download as PPTX, PDF
Dr. B.V.Parvathy
Dr. B.V.Parvathy

Abstract Aim: The aim of this study was to determine whether the combined connective tissue graft (CTG) with injectable plateletrich fibrin (iPRF) with coronally advanced flap (CAF) improved root coverage of deep Miller Class I or II gingival recessions com pared with CTG alone with CAF. Material and Methods: Seventytwo patients with Miller class I and II gingival reces sions were enrolled. Thirtysix patients were randomly assigned to the test group (CAF+CTG+iPRF [700 rpm for 3 min]) or control group (CAF+CTG). Clinical evalua tions were made at 6 months. Results:At 6months, complete root coveragewas obtained at 88% of the sites treated with CAF+CTG+iPRF and 80% of the sites treated with CAF+CTG. Difference be tween the two groups was not statistically significant. At 6 months, the recession depth (RD) reduction and increase in keratinized tissue height (KTH) of the test sites were significantly better compared with the control sites. Conclusions: According to the results, the addition of iPRF to the CAF+CTG treat ment showed further development in terms of increasing the KTH and decreasing RD. However, this single trial is not sufficient to advocate the true clinical effect of iPRF on recession treatment with CAF+CTG and additional trials are needed. KEYWORDS connective tissue graft, injectable plateletrich fibrin, root coverage

1 of 13
Download to read offline
CAF+CTG+iPRF.pptx
CLINICAL EVALUATION OF INJECTABLE PLATELETRICH FIBRIN WITH CONNECTIVE TISSUE GRAFT FOR THE TREATMENT OF DEEP GINGIVAL RECESSION DEFECTS: A CONTROLLED RANDOMIZED CLINICAL TRIAL SEPT 2019 Onur Ucak Turer, Mustafa Ozcan, Bahar Alkaya, Seren Surmeli, Gulsah Seydaoglu, Mehmet Cenk Haytac
INTRODUCTION Gold Standard Aroca 2009, Cairo 2014,Chen 2019, Tonetti 2014 in EWP. Chambrone et al 2010, Dolgun 2015 - Limitation Aroca et al 2009, Wang 2005, Barboza 2016 - Plasma Barboza 2016, Castro et al 2017, Miron et al 2017 Advantage Aroca et al 2009, Castro et al 2017, Miron et al 2017 PRF upon PRP
Castro et al 2017 Advantage of PRF Clinical use of PRF has been widely adopted in the treatment of GRs; however, the results are contradictory (Aroca et al 2009, Eren & Atilla 2012, 2014, Gupta et al 2015, Jankovic et al 2010, Keceli et al 2015, Kuka et al 2018, Thamaraiselvan, Elavarasu,Thangakumaran, Gadagi & Arthie 2015, Tunal脹 et al 2015). iPRF- Miron et al 2017 PRP-Miron et al 2019 & Blood clot-Varela et al 2019
AIM To determine whether the combination of CTG and autologous iPRF with CAF can improve the RC of isolated deep Miller Class I or II GRs compared to CTG alone with CAF.
MATERIALS AND METHODS Inclusion criteria 19 years of age, Periodontally and systemically healthy, FMPS and FMBS <15%, Presence of deep Miller Class I/II GR defect (3 mm in depth) at the buccal aspect of incisors and canines, Presence of identifiable CEJ (step 1 mm at CEJ level and/or presence of a root irregularity/abrasion with identifiable CEJ, was accepted), No previous periodontal surgery. Exclusion criteria Smoking, Contraindications for surgery, Presence of recession defects associated with caries, deep abrasion, restoration or pulpal pathology.
SURGICAL TECHNIQUES
CAF+CTG+iPRF.pptx
RESULTS
CAF+CTG+iPRF.pptx
DISCUSSION Aroca et al 2009 & Kuka et al 2018 CAF+PRF Eren & Atilla 2014, Jankovic et al 2010, Tunali et al CAF+CTG &CAF+PRF Keceli et al 2015 CAF+CTG+PRF & CAF+CTG Jenabian et al 2018 PRF diversity Aroca et al 2009 Disadvantage of PRF Sun et al 2014 Angiogenesis activity Al-Maawi et al 2018,Castro et al 2019, Cortellini et al 2018 Modification in i-PRF Guiha et al 2001 - Histological
REFERENCES
CAF+CTG+iPRF.pptx

More Related Content

CAF+CTG+iPRF.pptx

  • 2. CLINICAL EVALUATION OF INJECTABLE PLATELETRICH FIBRIN WITH CONNECTIVE TISSUE GRAFT FOR THE TREATMENT OF DEEP GINGIVAL RECESSION DEFECTS: A CONTROLLED RANDOMIZED CLINICAL TRIAL SEPT 2019 Onur Ucak Turer, Mustafa Ozcan, Bahar Alkaya, Seren Surmeli, Gulsah Seydaoglu, Mehmet Cenk Haytac
  • 3. INTRODUCTION Gold Standard Aroca 2009, Cairo 2014,Chen 2019, Tonetti 2014 in EWP. Chambrone et al 2010, Dolgun 2015 - Limitation Aroca et al 2009, Wang 2005, Barboza 2016 - Plasma Barboza 2016, Castro et al 2017, Miron et al 2017 Advantage Aroca et al 2009, Castro et al 2017, Miron et al 2017 PRF upon PRP
  • 4. Castro et al 2017 Advantage of PRF Clinical use of PRF has been widely adopted in the treatment of GRs; however, the results are contradictory (Aroca et al 2009, Eren & Atilla 2012, 2014, Gupta et al 2015, Jankovic et al 2010, Keceli et al 2015, Kuka et al 2018, Thamaraiselvan, Elavarasu,Thangakumaran, Gadagi & Arthie 2015, Tunal脹 et al 2015). iPRF- Miron et al 2017 PRP-Miron et al 2019 & Blood clot-Varela et al 2019
  • 5. AIM To determine whether the combination of CTG and autologous iPRF with CAF can improve the RC of isolated deep Miller Class I or II GRs compared to CTG alone with CAF.
  • 6. MATERIALS AND METHODS Inclusion criteria 19 years of age, Periodontally and systemically healthy, FMPS and FMBS <15%, Presence of deep Miller Class I/II GR defect (3 mm in depth) at the buccal aspect of incisors and canines, Presence of identifiable CEJ (step 1 mm at CEJ level and/or presence of a root irregularity/abrasion with identifiable CEJ, was accepted), No previous periodontal surgery. Exclusion criteria Smoking, Contraindications for surgery, Presence of recession defects associated with caries, deep abrasion, restoration or pulpal pathology.
  • 11. DISCUSSION Aroca et al 2009 & Kuka et al 2018 CAF+PRF Eren & Atilla 2014, Jankovic et al 2010, Tunali et al CAF+CTG &CAF+PRF Keceli et al 2015 CAF+CTG+PRF & CAF+CTG Jenabian et al 2018 PRF diversity Aroca et al 2009 Disadvantage of PRF Sun et al 2014 Angiogenesis activity Al-Maawi et al 2018,Castro et al 2019, Cortellini et al 2018 Modification in i-PRF Guiha et al 2001 - Histological